-
Sozzi: Auntie Anne's Business Is Doing Just Fine
Wednesday, June 8, 2016 - 2:12pm | 314Read More...Have you been to a mall lately? If so, chances are you observed that foot traffic isn't quite the same it has been in prior years. Call this the Amazon.com, Inc. (NASDAQ: AMZN) effect, as the online retailer is crushing traditional retailers. With that said, it might be a bit of a surprise to...
-
Opinion: Twitter Has Been 'Trending Lately,' But That's 'Not All Good News'
Wednesday, June 8, 2016 - 10:31am | 364Read More...The Street Real Money's Anders Keitz argued that while some Wall Street analysts continue to argue that Twitter Inc (NYSE: TWTR) is "ripe for a takeover," the company has been "trending lately;" however, these trends were "not all good news." Keitz noted one of Twitter's chief rivals, Snapchat,...
-
Citigroup CEO Estimates 25% Drop In Q2 Profits
Friday, June 3, 2016 - 1:20pm | 141Read More...Amid weak capital markets revenue and higher regulatory costs, Citigroup Inc (NYSE: C) CEO Michael Corbat expects a 25 percent drop in second quarter profit. At an investor conference in New York, Corbat said he expects a flat quarterly profit in the second quarter versus the first quarter of...
-
Chiasma Plunges 14%; Feuerstein Source Says FDA Will Reject Co.'s Therapy Capsules
Thursday, April 14, 2016 - 10:05am | 258Read More...Shares of Chiasma Inc (NASDAQ: CHMA) plunged more than 14 percent Thursday morning ahead of the U.S. Food and Drug Administration's decision on Friday to approve or reject the company's therapy. Chiasma is a biopharmaceutical company that focuses on the treatment of orphan diseases. The...
-
Clovis Oncology Falls 8%: Here's What You Need To Know
Friday, April 8, 2016 - 2:11pm | 320Read More...Shares of Clovis Oncology Inc (NASDAQ: CLVS) lost more than 8 percent on Friday after the company confirmed that the FDA posted briefing documents ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib. The...
-
Pacific Sunwear Killed By Bloomberg Bankruptcy Prep Report
Tuesday, April 5, 2016 - 9:59am | 272Read More...Shares of Pacific Sunwear of California, Inc. (NASDAQ: PSUN) plunged nearly 40 percent early Tuesday morning following a report by Bloomberg the company is preparing to file for Chapter 11 bankruptcy. The Boston Globe, citing Bloomberg's report, noted that a Chapter 11 filing could come as early as...
-
Jabil's Guidance Is Bad Sign For Apple's iPhone
Thursday, March 17, 2016 - 12:06pm | 507Read More...Jabil Circuit, Inc. (NYSE: JBL) announced some disappointing guidance – disappointing to the degree that it may spell trouble for one of its major customers Apple Inc. (NASDAQ: AAPL). While the Street's expectation for FQ3 DMS revenue for Jabil was at +16.4 percent prior to the...
-
Sarepta Therapeutics Gives Up Gains Following Notable Tweet
Tuesday, February 23, 2016 - 3:29pm | 313Read More...Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher on heavy volume and hit an intra-day high of $15.74 Tuesday afternoon. Sarepta's gain was short-lived as the stock quickly gave up all gains and was trading lower by more than 2 percent mid-Tuesday afternoon. Investors and...
-
Will Apple Be Netflix's Next Contender? New Reports Suggest Apple's Training For The Arena
Friday, January 29, 2016 - 12:40pm | 357Read More...It's been a big week for Apple Inc. (NASDAQ: AAPL). Following a mixed Q1 2016 earnings report on Tuesday, the stock experienced some rollercoaster-like movements, closing down 6.5 percent on Tuesday, slightly rebounding during Wednesday, settling lower Thursday and attempting a mild rebound...
-
Adam Feurestein Reminds Twitter Followers 'Today Is Merck's HepC elbasvir/grazoprevir PDUFA'
Thursday, January 28, 2016 - 12:48pm | 302Read More...The Street's biotechnology and drug stock expert, Adam Feuerstein, reminded his Twitter followers of an important event with the healthcare space. Reminder: Today is $MRK HepC elbasvir/grazoprevir PDUFA. Co. spox knows first and most important post-approval question is: What price? — Adam...
-
Following Goldman Sachs' Downgrade, Caterpillar Drops 4.3%
Monday, January 25, 2016 - 3:40pm | 257Read More...Shares of Caterpillar Inc. (NYSE: CAT) took a hit in Monday's afternoon trading session, lower by 4.3 percent at the time of this publication. The drop follows Goldman Sachs's downgrade of the heavy equipment maker's stock to Sell from Neutral on expectations of lower returns on capital amid lower...
-
Relypsa Lost Major Ground; Feuerstein Tweets Favus Report Said 'Nothing New'
Friday, January 8, 2016 - 9:17am | 331Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 8 percent early Friday morning. The stock plunged more than 13 percent on Thursday following a bear research report by Elliot Favus of Favus Institutional Research. Adam Feuerstein, a senior columnist with The Street and known...
-
Why Would Urban Outfitters Get Into The Restaurant Business?
Monday, November 16, 2015 - 2:09pm | 427Read More...Shares of Urban Outfitters, Inc. (NASDAQ: URBN) lost nearly 10 percent on Monday. Urban Outfitters announced it has agreed to acquire the Vetri Family group of restaurants, including the popular Pizzeria Vetri. The question investors are asking is simply, "Why would a retailer acquire a...
-
Doug Kass Pounds The Table On Netflix: Sell!
Friday, July 17, 2015 - 9:40am | 415Read More...Douglas Kass is the Manager of Seabreeze Partners and a Contributor to Real Money Pro at The Street. In an article published Friday, Kass stated that he doesn't "have a dog in the Netflix, Inc. (NASDAQ: NFLX) hunt" but if he was "fortunate" to hold shares of the...
-
Why Should Nike Want Tiger Woods, Not Rory McIlroy, To Win The Masters?
Thursday, April 9, 2015 - 8:48am | 327Read More...Belus Capital Advisors CEO Brian Sozzi argued that Nike Inc (NYSE: NKE) may prefer Tiger Woods to win the upcoming Masters tournament over Rory McIlroy. In an article published Wednesday on The Street, Sozzi said the issue at hand is the fact that the 39-year-old Woods is still Nike's "go to" guy...













